Cryptomeningitis incidence 1.32% among HIV patients in Indian clinic

Cryptococcal meningitis (cryptomeningitis) was diagnosed in 91 of 6,900 HIV‑infected patients (1.32%) at a tertiary care immunodeficiency clinic, highlighting a high‑mortality burden for this opportunistic infection【1】.

Patient profile and disease timing

The cohort spanned January 2002 to March 2011. Of the 91 diagnosed patients, 68 presented with cryptococcal meningitis as the initial illness, while nine developed meningitis within six months of starting antiretroviral therapy (ART) and six had been on ART for more than six months before diagnosis【1】. The remaining eight patients were not on ART at the time of infection. The mean baseline CD4 count was 77.7 ± 61 cells/µL, and 74 patients (≈81%) had CD4 < 100 cells/µL at diagnosis, underscoring severe immunosuppression as a key risk factor【1】.

Outcomes and risk factors

During follow‑up, 37 patients died, yielding a mortality rate of 0.54% across the screened population (37/6,900)【1】. No statistical link was found between survival and the duration of ART at the time of cryptomeningitis onset (Pearson χ² = 0.241, p = 0.884)【1】. However, a significant difference in CD4 counts existed between survivors and non‑survivors (Pearson χ² = 9.1, df = 4, p = 0.05)【1】, indicating that lower CD4 levels correlated with higher mortality.

Treatment context

Eleven patients experienced relapse while on maintenance fluconazole, suggesting challenges in long‑term fungal suppression despite standard therapy【1】. The study reinforces the importance of early detection and aggressive management of cryptococcal infection in AIDS care, particularly in settings with limited resources.

What to watch

• CD4 thresholds: Patients with CD4 < 100 cells/µL remain at heightened risk; monitoring CD4 trends can flag vulnerability.
• ART timing: Although duration of ART did not correlate with survival in this cohort, early initiation of effective ART remains a cornerstone of AIDS management.
• Fluconazole relapse: Relapse rates (≈12% of cases) warrant vigilance for adherence and possible drug resistance.

The 1.32% prevalence and associated mortality underscore cryptomeningitis as a persistent threat in HIV care, especially for those with profound immunosuppression. Further research is needed to clarify optimal prophylactic and therapeutic strategies to reduce relapse and improve survival.